AI-Assisted Village Doctors and Rural Primary Healthcare: A Randomized Controlled Trial in China

How to cite

Lin, Wei; Yuan, Zhe. 2026. "AI-Assisted Village Doctors and Rural Primary Healthcare: A Randomized Controlled Trial in China." AEA RCT Registry. AEARCTR-0019289. https://doi.org/10.1257/rct.19289-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Wei Lin* , Zhe Yuan

* Primary investigator

Registry ID
AEARCTR-0019289
DOI
https://doi.org/10.1257/rct.19289-1.0
First registered
Last updated
Status
In development
Trial dates
2026-08-11 – 2028-09-30
Countries
Private
JEL codes
I12, I15, I18, O33, J24, C93
Registry record
http://www.socialscienceregistry.org/trials/19289

Abstract

Village doctors in rural China are often few in number, aging, and have limited formal training, while chronic disease burdens are rising. This study evaluates whether giving village doctors access to an AI health assistant app ("Ant AFu," developed by Ant Group), along with structured training and support, changes how they deliver care. We conduct a village-level randomized controlled trial in a mountainous county in Guizhou Province, China, covering all 140 administrative villages. Villages are randomly assigned within townships to one of four groups: two groups where village doctors receive AI training and app access (in one of these, villagers are also encouraged to use the app), and two groups that continue current practice during the study period and receive delayed access afterward. We measure outcomes including how many patients doctors see, the quality of diagnosis and prescribing (assessed through case reviews, clinical scenarios, and unannounced standardized-patient visits), and patient recovery, using doctor surveys, monthly case records, and phone follow-ups with patients. We also study how doctors actually use the app, drawing on de-identified usage data, and whether any improvements persist after access to the tool is temporarily withdrawn for a subset of doctors.

Intervention

Village doctors in treatment villages receive standardized training on an AI health assistant app ("Ant AFu," developed by Ant Group) and supported access to the app for use in their daily clinical work. Training covers the app's core functions, guidance on when AI input is and is not appropriate, how to incorporate the tool into diagnosis, prescribing, chronic-disease follow-up, and home visits, and how to recognize high-risk cases requiring referral. Training is followed by hands-on practice with simulated and common real-world cases, and by several weeks of follow-up support (group chat/phone-based Q&A and periodic check-ins) after initial rollout, plus periodic refresher sessions and targeted outreach to low-usage doctors during the intervention period. There are two treatment arms: in one, only village doctors receive training and app access; in the other, villagers in the same villages are also encouraged and supported to use the app themselves. Villages in the two control arms continue current practice during the study period and are offered the same training after the endline survey (delayed treatment).

Experimental design

This is a village-level cluster-randomized controlled trial conducted in a mountainous county in Guizhou Province, China, covering all 140 administrative villages in the county. After a baseline survey of village doctors and clinics, villages are randomly assigned within townships (stratified randomization) to one of four arms of 35 villages each: (1) Treatment 1, in which village doctors receive standardized training and supported access to an AI health assistant app; (2) Treatment 2, which adds village-level promotion of the app to residents; and (3)-(4) two control arms that continue existing practice during the study period, with the same training offered after the study ends. Randomization is stratified within townships to balance village population, doctor gender, and doctor education. The intervention period lasts approximately 6 months, with a baseline survey beforehand and an endline survey afterward (total study duration approximately 12-13 months). Outcomes are measured through doctor surveys, monthly case-record collection, sampled patient phone follow-up, household surveys, and standardized clinical assessment methods, with analysis conducted at the village level using intention-to-treat comparisons and village-clustered standard errors.

Design details

Randomization method
Randomization was conducted in office using a computer-generated randomization procedure (stratified randomization within townships), implemented after completion of the baseline village/doctor survey. Balance across arms was verified using standardized difference tests on stratification and key baseline covariates.
Randomization unit
Administrative village (cluster). All doctors and patients within a given village clinic receive the same treatment assignment as their village. There is a single level of randomization (village-level, stratified within townships); the post-intervention access-withdrawal sub-study introduces a second, later-stage individual (doctor-level) randomization within the pool of previously treated doctors.
Clusters
140 villages
Observations
Approximately 210 village doctors (1-2 doctors per village, 1.5 average across 140 villages) and approximately 1,400 patients (10 average across 140 villages sampled per village for follow-up), plus village-level administrative records and de-identified app usage data covering all 140 villages.
Arms
35 villages - Control Arm 1 (existing practice maintained; delayed training after endline) 35 villages - Control Arm 2 (existing practice maintained; delayed training after endline) 35 villages - Treatment 1 (village doctor training + AI app access) 35 villages - Treatment 2 (village doctor training + AI app access + villager-level promotion of app use)
Primary outcomes
(1) Service coverage: monthly number of unique patients seen per doctor, total monthly patient volume, monthly chronic-disease follow-up visits completed. (2) Quality of diagnosis and prescribing: a standardized diagnostic/prescribing quality score derived from (a) audited case records for tracer conditions, (b) doctor performance on standardized clinical vignettes, and (c) doctor behavior recorded during unannounced standardized patient (SP) visits. (3) Patient recovery: symptom improvement, self-reported recovery, repeat visits/ hospitalization, and adherence to prescribed treatment, measured via phone follow-up at fixed intervals after the index visit (e.g., day 7/14 for acute conditions, day 30/90 for chronic conditions).
Secondary outcomes
(1) Depth/quality of home visits and follow-up (a constructed home-visit-depth index). (2) Patient costs and time use: total visit cost, drug cost, referral/travel cost, time lost from work, and time from symptom onset to treatment. (3) Doctor knowledge, confidence, and behavior change: vignette test scores, case judgment accuracy, self-reported confidence, willingness to conduct follow-up visits or take on more complex cases. (4) Safety indicators: rate of clearly inappropriate prescriptions, antibiotic/steroid overuse rates, missed danger-sign rate, delayed-referral rate, and patient adverse events. (5) Mechanism/usage indicators: app activation, weekly/monthly active use, number of queries per session, functions used (symptom check, report interpretation, follow-up support, health education), and whether promotion to village doctors generates spillover use among villagers (in Treatment 2 villages).

Cited by

No citation data available for this registration yet.

Keywords